Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,561 | -5,059 | -3,762 | -2,342 | 1,052 |
| Depreciation Amortization | 546 | 404 | 265 | 131 | 631 |
| Accounts payable and accrued liabilities | 242 | 613 | 1,034 | 838 | 134 |
| Other Working Capital | 94 | 579 | 1,119 | 916 | 296 |
| Other Operating Activity | -375 | -806 | -951 | -810 | -8,140 |
| Operating Cash Flow | $-6,054 | $-4,268 | $-2,294 | $-1,266 | $-6,028 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-7 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 450 | 450 | 450 | N/A | 3,991 |
| Debt Issued | 117 | 117 | 117 | N/A | N/A |
| Common Stock Issued | 6,134 | 6,096 | N/A | N/A | 5,999 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -3,986 |
| Financing Cash Flow | $6,701 | $6,663 | $567 | $N/A | $6,005 |
| Beginning Cash Position | 1,835 | 1,835 | 1,835 | 1,835 | 1,858 |
| End Cash Position | 2,474 | 4,229 | 107 | 568 | 1,835 |
| Net Cash Flow | $640 | $2,395 | $-1,728 | $-1,266 | $-23 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,054 | -4,268 | -2,294 | -1,266 | -6,028 |
| Capital Expenditure | -7 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -6,061 | -4,268 | -2,294 | -1,266 | -6,028 |